Cargando…

P1001: DNMT3A/TET2/ASXL1 MUTATIONS DETERMINE THROMBOTIC RISK IN POLYCYTHAEMIA VERA

Detalles Bibliográficos
Autores principales:	Segura Diaz, A., Stuckey, R., Florido Ortega, Y., Sobas, M., Álvarez Larrán, A., Ferrer-Marín, F., Pérez Encinas, M., Carreño, G., Fox, M., Tazón Vega, B., Cuevas, B., López Rodriguez, J., Farías Sánchez, N., Bilbao Sieyro, C., Gómez Casares, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430134/ http://dx.doi.org/10.1097/01.HS9.0000846872.78429.a1

Ejemplares similares

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations
por: Segura-Díaz, Adrián, et al.
Publicado: (2020)

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera
por: Stuckey, Ruth, et al.
Publicado: (2021)

Koilonychia and Polycythæmia Vera
por: Glazebrook, A. J.
Publicado: (1944)

Unusual Neurological Symptoms in Polycythæmia Rubra Vera
por: Grunberg, A., et al.
Publicado: (1950)

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera
por: Tiong, I S, et al.
Publicado: (2016)

The treatment of polycythaemia vera: an update in the JAK2 era
por: Finazzi, G., et al.
Publicado: (2007)

Polycythæmia Vera with Tuberculosis Splenomegaly. Report of a Case
por: Guild, A. A., et al.
Publicado: (1950)

Splenic Infarctions in Polycythaemia Vera are Not Always a Catastrophe
por: Abdalla, ELMustafa, et al.
Publicado: (2022)

Improvement in polycythaemia vera after parathyroidectomy for primary hyperparathyroidism
por: Sthaneshwar, Pavai, et al.
Publicado: (2022)

Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2021)

The epidemiology of polycythaemia rubra vera in England and Wales 1968-1982.
por: Prochazka, A. V., et al.
Publicado: (1986)

Crescentic Glomerulonephritis Associated with Polycythaemia Vera: A Rare Occurrence
por: Dwivedi, Rohan, et al.
Publicado: (2022)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Haemoglobinopathia Ypsilanti – A rare, but important differential diagnosis to polycythaemia vera()
por: Nygaard, Marietta, et al.
Publicado: (2013)

MTAP-related increased erythroblast proliferation as a mechanism of polycythaemia vera
por: Tipgomut, Chartsiam, et al.
Publicado: (2021)

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
por: Mathur, Abhinav, et al.
Publicado: (2022)

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
por: Amé, Shanti, et al.
Publicado: (2023)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
por: Traina, Fabiola, et al.
Publicado: (2012)

Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations
por: Ibrahim, Ibrahim Khidir, et al.
Publicado: (2019)

Delayed diagnosis of polycythaemia vera in an adult female with non-cirrhotic portal hypertension
por: Tachi, Kenneth, et al.
Publicado: (2022)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
por: Carpenter, Lewis, et al.
Publicado: (2022)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma
por: Belani, R, et al.
Publicado: (2014)

Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
por: Stuckey, Ruth, et al.
Publicado: (2023)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline
por: McMullin, Mary F. F., et al.
Publicado: (2018)

Polycythaemia treated with nephrectomy
por: Thuesen, Anne Daugaard, et al.
Publicado: (2011)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
por: Palandri, Francesca, et al.
Publicado: (2023)

JAK2 and TET2 Mutation in Polycythemia Vera
por: Padda, Jaskamal, et al.
Publicado: (2021)

Polycythaemia Vera JAK 2 Mutation in a Patient with Underlying Chronic Obstructive Pulmonary Disease at a Primary Care Setting
por: Mahmud, Rafidah, et al.
Publicado: (2020)

Real-World Clinical Characterisation of Polycythaemia Vera Patients from a Prospective Registry in Portugal: Is Resistance to Hydroxyurea a Reality?
por: Sarmento, Maria, et al.
Publicado: (2023)

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2020)

Successful treatment of proton pump inhibitor induced sporadic fundic gland polyps with an argon plasma coagulator in a patient with polycythaemia vera
por: Kato, Kazuya, et al.
Publicado: (2017)

MONO 1001
por: Pacquet, J Y, et al.
Publicado: (2002)

Chronic Cyanosis, with Polycythæmia and Enlarged Spleen
por: Begg, C., et al.
Publicado: (1905)

A Case of Erythræmia or Splenic Polycythæmia
por: Parker, G.
Publicado: (1920)

DNMT3a and TET2 in adipocyte insulin sensitivity
por: Villivalam, Sneha Damal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q9eqoh43r6mtfvnnl78qvfl8t6